Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Hedner

Showing results (401-410 of 406) with videos related to

Pageof 41
Sort By:
You have reached the last page of results.This site can display upto 406 results.
Blood Pressure|March 12, 1998
The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current statusL Hansson, T Hedner, L Lindholm, et al.
Lancet (London, England)|February 25, 1999
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialL Hansson, L H Lindholm, L Niskanen, et al.
Diabetes Care|February 13, 2008
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial, G R Dagenais, H C Gerstein, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
Hypertension (Dallas, Tex. : 1979)|December 18, 1998
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in HypertensionB Dahlöf, R B Devereux, S Julius, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|February 19, 2002
Amelioration of arterial properties with a perindopril-indapamide very-low-dose combinationR G Asmar, G M London, M E O'Rourke, et al.
Pageof 41

Showing results (401-410 of 406) with videos related to

Sort By:
Pageof 41
You have reached the last page of results.This site can display upto 406 results.
Blood Pressure|March 12, 1998
The Captopril Prevention Project (CAPPP) in hypertension--baseline data and current statusL Hansson, T Hedner, L Lindholm, et al.
Lancet (London, England)|February 25, 1999
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialL Hansson, L H Lindholm, L Niskanen, et al.
Diabetes Care|February 13, 2008
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial, G R Dagenais, H C Gerstein, et al.
American Journal of Hypertension|July 1, 1997
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study GroupB Dahlöf, R Devereux, U de Faire, et al.
Hypertension (Dallas, Tex. : 1979)|December 18, 1998
Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in HypertensionB Dahlöf, R B Devereux, S Julius, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|February 19, 2002
Amelioration of arterial properties with a perindopril-indapamide very-low-dose combinationR G Asmar, G M London, M E O'Rourke, et al.
Pageof 41